论文部分内容阅读
目的研究基因重组人红细胞生成素（Ｅｐｏ）替代治疗慢性肾功能衰竭（ＣＲＦ）患者贫血对心血管系统的影响。方法２２例ＣＲＦ血液透析贫血患者，使用Ｅｐｏ（４．６±１．２月）前后应用二维彩色心动超声图及放免法测定血管活性物质肾素（ＰＲＡ）、血管紧张素Ⅱ（ＡｎｇⅡ）、醛固酮（Ａｌｄ）及血液动力学变化。结果随着贫血的纠正，ＰＲＡ，ＡｎｇⅡ和Ａｌｄ无明显变化。心率、心排出量、心排指量均显著降低（Ｐ＜０．０５）；总外周血管阻力显著增高（Ｐ＜０．０１）。结论ＣＲＦ患者Ｅｐｏ治疗后其心脏收缩功能改善。
Objective To investigate the effects of recombinant human erythropoietin (Epo) on cardiovascular system in patients with chronic renal failure (CRF). Methods Twenty-two patients with CRF hemodialysis anemia were enrolled in this study. Before and after Epo (4.2 ± 1.2 months), two-dimensional color echocardiography and radioimmunoassay were used to measure the plasma levels of vasoactive substance (PRA), angiotensin Ⅱ (AngⅡ) Aldosterone (Ald) and hemodynamic changes. Results With the correction of anemia, PRA, Ang Ⅱ and Ald did not change significantly. Heart rate, cardiac output and cardiac output were significantly decreased (P <0.05), and total peripheral vascular resistance was significantly increased (P <0.01). Conclusion CRF patients with Epo treatment of cardiac systolic function improved.